Sulfazine

Quick links to important sections

Sulfazine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfazine

Quick Facts

Property Description
Active ingredient Sulfasalazine (SSZ)
Form Oral tablets, Enteric-coated tablets
Pharmacological class Disease-Modifying Antirheumatic Drug (DMARD)
Common use Management of chronic inflammation
Origin Synthetic organic molecule, Prodrug

Defining Sulfazine: A Disease-Modifying Antirheumatic Drug (DMARD)

Sulfazine is a medicine containing the active ingredient Sulfasalazine (SSZ), a synthetic organic molecule classified as a Disease-Modifying Antirheumatic Drug (DMARD) and a broad anti-inflammatory agent. This dual classification reflects its specialized role in treating conditions driven by chronic inflammation and immune system activity. Sulfasalazine is an agent used to control underlying inflammatory processes rather than just treating symptoms, a role utilized for its long-term benefits in chronic inflammatory conditions.

Unlike common anti-inflammatory medications that provide rapid, short-term relief, Sulfasalazine is considered a non-biologic DMARD designed to alter the underlying disease processes over a sustained period. Its formal chemical identifier is Salicylazosulfapyridine. As a DMARD, its overarching purpose is to provide long-term management of inflammatory disorders, with the goal of stabilizing the condition and reducing the progression of tissue damage.

Composition and Origin: The Dual-Action Prodrug

Sulfasalazine functions as a prodrug, meaning the molecule is initially inactive and requires processing by the body to become effective, which occurs through the action of intestinal bacteria. Chemically, it is composed of two linked active parts: 5-Aminosalicylic acid (5-ASA) and Sulfapyridine (SP).

For oral route of administration, the medicine is commonly supplied as tablets or, frequently, as enteric-coated tablets (Delayed-release tablets). The enteric-coated form is specifically engineered to ensure the prodrug reaches the colon intact before being broken down into its two therapeutically active components, which serves as a necessary delivery mechanism.

General Benefit: Managing Chronic Inflammation

The general benefit of Sulfazine stems from the combined anti-inflammatory and immunomodulatory properties of its two released components. By targeting both localized inflammation in the bowel (5-ASA) and systemic immune system activity (Sulfapyridine), the drug helps to mitigate chronic inflammatory processes.

This dual-action approach is intended for managing the multifaceted nature of long-term inflammatory and autoimmune disorders, allowing the medicine to address both the direct tissue irritation and the underlying immune dysfunction that causes persistent swelling and pain. This molecule is utilized for the management of these chronic inflammatory states.

Regulatory References

  1. DMARD
  2. NIH Fact Sheet

What side effects are possible with Sulfazine?

Possible Side Effects and Safety Information

The safety profile of Sulfazine (Sulfasalazine) is officially categorized by potential adverse reactions and system-specific safety considerations documented in regulatory labeling. Adverse effects are classified by frequency, ranging from very common to not known.

Adverse Reaction Frequency and System-Organ Classes

The most frequent reactions primarily involve the Gastrointestinal and Nervous Systems.

Classification Examples of Officially Listed Adverse Reactions
Very Common ( ge 1/10) Headache, nausea, gastric distress, anorexia (loss of appetite).
Common ( ge 1/100 to < 1/10) Leukopenia (decreased white blood cells), fever, dizziness, pruritus, rash, taste disorders.

Serious adverse reactions are also officially documented, including severe Blood and Lymphatic System Disorders such as agranulocytosis and aplastic anemia, and life-threatening systemic hypersensitivity reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These severe events are generally classified as rare or frequency not known, and the risk for severe cutaneous reactions is noted as being highest early in the course of therapy.

Safety Considerations and Restrictions

Specific safety notes address particular populations and physiological processes. Reversible oligospermia (decreased sperm count) and infertility are documented safety observations in men which typically resolve upon discontinuation of the medicine. The medication inhibits the absorption of folic acid, which may be associated with blood disorders. Furthermore, the label requires caution for use in individuals with pre-existing hepatic or renal damage or a history of specific conditions, such as porphyria or intestinal obstruction.

Overdose and Emergency Response

Sulfasalazine overdosage is defined by clinical manifestations that range from gastrointestinal distress to severe central nervous system effects. Officially documented initial symptoms include Nausea, Vomiting, Gastric distress, and Abdominal pains. In more serious overdosage situations, the manifestations may progress to include Drowsiness and Convulsions or Seizures. The incidence and severity of toxicity are directly linked to the total measured Serum sulfapyridine concentration.

Immediate medical assistance must be sought upon any suspected overdosage. The official regulatory guidance mandates contacting a poison control center or emergency services at once. Specific life-threatening signs that require calling emergency services immediately include Collapse, having a Seizure, or experiencing Trouble breathing.

No specific antidote for Sulfasalazine overdosage is documented in regulatory labeling; therefore, management is symptomatic and supportive. Procedures may focus on decontamination, such as Gastric lavage or Emesis, and on enhancing the drug's elimination. Supportive measures documented in official prescribing information include Alkalinizing urine and Forcing fluids, provided kidney function is normal. Severe complications such as Anuria or Complete renal blockage by crystals may necessitate advanced procedures like Dialysis or Catheterization of the ureters.

Therapeutic Uses of Sulfazine

What Sulfazine Treats: Main Uses and Benefits

Sulfasalazine is an anti-inflammatory medication used for the management of conditions involving inflammatory or irritative processes. It is commonly used in clinical settings that involve acute or unstable symptom patterns.

The medication is utilized for easing symptoms in key areas, including Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Polyarticular Juvenile Idiopathic Arthritis (PJIA). It is used to address symptoms related to inflammatory or irritative states such as joint swelling and gastrointestinal discomfort.

In these conditions, the medicine provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. It is often used during phases when symptoms become more noticeable.

“It assists with maintaining functional stability when symptoms are more noticeable.”

This medication may assist with symptoms that interfere with daily functioning and is commonly used when short-term symptomatic assistance is needed.


Quick Fact: Support for Inflammatory Discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Sulfazine (Sulfasalazine) is contraindicated and must not be used in several patient populations, based strictly on official regulatory labeling.

Contraindications and Absolute Non-Eligibility

Absolute prohibitions include individuals with a known hypersensitivity to sulfasalazine, sulfonamides (sulfa drugs), or salicylates. The medicine is also strictly contraindicated in patients with porphyria, intestinal or urinary obstruction, and in pediatric patients under two years of age. Use is also cautioned against in cases of severe hepatic or severe renal impairment.

Age-Based and Conditional Eligibility

Age Group Eligibility Status
Infants (< 2 yrs) Contraindicated (Must not use)
Children (≥ 6 yrs) Approved for established uses (RA, PJIA, UC)
Older Adults Use established; caution advised for monitoring

Conditional use (restricted use) is required for patients with G6PD deficiency, mild to moderate hepatic or renal damage, or a history of severe allergy or bronchial asthma. The drug is not recommended for children with Systemic Onset Juvenile Rheumatoid Arthritis (SoJRA).

Reproductive Status

Use during pregnancy is classified as Pregnancy Category B (US) and permitted only if clearly needed. The label documents that the drug passes into breast milk and that it may cause reversible oligospermia (low sperm count) in men.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Sulfazine (Sulfasalazine) identifies specific interaction patterns that can alter drug exposure or increase the risk of shared toxic effects when co-administered with other products. This information is derived exclusively from official government labeling, such as FDA Prescribing Information and EMA regulatory data.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance / Category Official Regulatory Outcome
Contraindicated Combination Methenamine Co-administration is formally prohibited due to the documented risk of forming an insoluble urinary precipitate (P.D. Interaction).
Exposure Reduction (P.K.) Digoxin Reduced absorption of Digoxin is reported, resulting in lower plasma levels and decreased therapeutic effect.
Nutrient Interference (P.K.) Folic Acid (Vitamin B9) Reduced absorption is documented, which may result in a recognized folate deficiency.
Additive Toxicity (P.D.) Oral Hypoglycemic Agents Increased risk of hypoglycemia is documented due to shared chemical properties.
Additive Toxicity (P.D.) Methotrexate and Myelosuppressive Agents Increased risk of myelosuppression is documented due to additive toxic effects.
Transporter Effect (P.K.) Apalutamide / Acalabrutinib Affects Sulfazine exposure via documented BCRP induction (Apalutamide) or BCRP inhibition (Acalabrutinib).

The official interaction structure is defined by both pharmacodynamic synergism and pharmacokinetic changes leading to altered concentrations of co-administered drugs. No mandatory time-separation rules are formally documented in regulatory labeling to manage these interactions.

Mechanism of Action

How Sulfazine Works

Sulfazine (Sulfasalazine) influences cellular signaling within mechanisms driven by cellular inflammatory mediators through a coordinated, dual-level pharmacodynamic action involving its two active components, 5-Aminosalicylic acid (5-ASA) and Sulfapyridine (SP). This mechanism requires the molecule to be cleaved by intestinal bacteria, leading to a slow onset of systemic mechanistic activity.

Local Enzyme Inhibition and Free Radical Scavenging

This domain covers the action of 5-ASA, which remains largely concentrated at the peripheral tissue level. It acts by directly inhibiting the 5-Lipoxygenase (5-LO) enzyme, thereby suppressing the production of inflammatory mediators called Leukotrienes. Additionally, 5-ASA neutralizes Reactive Oxygen Species (ROS). These actions initiate a rapid (relative to SP) reduction in the recruitment and activity of inflammatory cells, resulting in reduced chemotaxis and granulocyte degranulation at the tissue level.

Systemic Immunomodulation and Transcriptional Blockade

This domain encompasses the systemic effects of the absorbed Sulfapyridine (SP) and the parent drug, Sulfasalazine (SSZ). SP modulates the function of systemic immune cells like B-cells and suppresses the release of key pro-inflammatory cytokines (e.g., TNF-alpha). Furthermore, SSZ blocks the activation of the NF-kappaB transcription factor, a fundamental molecular switch that commands cells to produce inflammatory proteins. This mechanism maintains modulation of cellular activity associated with processes of sustained immune activation.

Dosage and Administration Information

How to Use Sulfazine — Administration Guidelines

Administration of Sulfasalazine follows established protocols regarding route, quantity, and timing to ensure continuous medication presence. The primary route is Oral (tablets or enteric-coated tablets), though a Rectal route via suppositories is also used for localized treatment of the distal colon.


Dosage and Schedule

The total daily dose is typically administered in divided doses, with intervals for ulcerative colitis (UC) induction often not exceeding eight hours. Dosing for Rheumatoid Arthritis (RA) involves a gradual dose titration, where treatment begins at a low dose (e.g., 500 mg once or twice daily) and is systematically increased over several weeks until the standard maintenance dose of 2 grams per day (2,000 mg/day) is reached. The maximum daily dose for UC induction therapy is constrained to 4 grams per day.


Preparation and Intake Rules

For proper administration, enteric-coated tablets must be swallowed whole and must not be crushed or chewed, as this action compromises the specialized coating designed for intestinal delivery. The medicine is generally directed to be taken after meals or with food. Furthermore, maintaining adequate fluid intake throughout the treatment period is an explicit procedural requirement. For children aged six years and older, dosing is weight-based (mg/kg/day) and divided into multiple daily doses. Treatment often continues as long-term maintenance even after the initial condition has stabilized.

Recent Clinical Evidence

Research Evidence / Overview of studies for Sulfazine

Evidence for Use in Rheumatoid Arthritis (RA)

Research primarily includes Randomized Controlled Trials (RCTs) and Meta-analyses in adults with active RA. Studies monitored outcomes related to physical discomfort, functional imbalance, and joint counts. Research also included evaluating changes on X-rays to assess joint damage progression. Findings describe patterns observed in the studies related to composite disease activity scores. Long-term effects are not fully established by extensive RCTs, and data comparing Sulfazine against many newer agents remains insufficient.


Evidence for Use in Ulcerative Colitis (UC)

Sulfazine was studied for UC through RCTs and Systematic Reviews for both induction and maintenance of remission. Studies monitored outcomes linked to inflammatory or irritative states, such as clinical remission rates and endoscopic appearance. Trials dedicated to maintenance reported that measured relapse frequency differed between the groups observed. Comparative evidence shows that studies observed varying rates of patient discontinuation due to reported adverse events when comparing Sulfazine to certain other 5-ASA treatments.


Evidence in Specific Patient Groups and Uncertainty

Evidence for Polyarticular Juvenile Idiopathic Arthritis (PJIA) consists of controlled trials in pediatric patients (typically ages 6 to 16) and extended observational follow-up up to nine years. This long-term, observational nature means certainty remains low compared to controlled trial data. Across all indications, follow-up durations were limited in many controlled trials, and sample sizes were modest in some original studies, influencing the certainty of the findings. Data for certain groups remain insufficient, particularly older adults or patients with significant comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Sulfazine (FAQ)

Q: How quickly should I expect Sulfazine to start working?

According to official product information, the medicine requires time to begin modifying disease processes. For conditions like Rheumatoid Arthritis (RA), clinical improvement may typically take 1 to 3 months before any effects are noticeable.

Q: Why do some people experience stomach upset with Sulfazine?

Official documents note that Sulfazine is a prodrug, meaning it must be broken down by bacteria in the intestines to become active. This enzymatic process in the gut is documented as being associated with common gastrointestinal symptoms, such as stomach upset and nausea.

Q: Are there any long-term side effects associated with Sulfazine?

Official documents address long-term safety by documenting risks of blood disorders, liver, and kidney damage. The safety profile also includes a specific mention of reversible oligospermia (decreased sperm count) in men, which is typically observed to resolve when the medicine is stopped.

Q: Are there specific vitamins or supplements to avoid while on Sulfazine?

Regulatory documents specifically describe how this medication can reduce the body's ability to absorb folic acid (Vitamin B9). This known nutrient interference may require adjustments, and official information suggests that all supplements should be reviewed by a prescribing professional.

Q: Can older adults use Sulfazine safely?

The use of Sulfazine is established in older adults, but official information requires caution and monitoring in this group. This is due to documented findings of a prolonged half-life, which means the drug may remain in the system longer.

Q: Can Sulfazine affect my ability to drive or operate machinery?

Due to documented common side effects such as dizziness and headache, a person's ability to safely drive or operate complex machinery may potentially be affected. Official safety information advises individuals to note how the medicine affects them regarding such activities.

Q: Why do official documents mention the need for regular blood monitoring with Sulfazine?

Official documents require regular monitoring because the medication carries risks of serious blood disorders, liver damage, and kidney problems. Frequent laboratory checks are necessary to facilitate the identification of potential issues in these systems.

Q: Are there specific symptoms that mean I need urgent medical attention while taking Sulfazine?

Yes, official patient safety information includes instructions to contact a healthcare provider immediately if serious signs develop. This includes a severe rash, fever, sore throat, or yellowing of the skin or eyes, as these can signal severe conditions like life-threatening skin reactions or blood disorders.

Q: Is Sulfazine considered an antibiotic?

Official documents classify Sulfazine as a Disease-Modifying Antirheumatic Drug (DMARD) and an anti-inflammatory agent. Its primary approved purpose is the management of chronic inflammation, not the treatment of common bacterial infections.

Q: What happens if I stop taking Sulfazine suddenly?

Official patient information states individuals must not stop taking the medication suddenly. Regulatory documents note that any changes to the medication schedule should be reviewed by a healthcare professional.

Q: Is it normal to feel tired when starting Sulfazine?

Unusual tiredness or weakness is listed as a documented adverse reaction in the official adverse reaction tables for this medication.

Q: Does Sulfazine cause hair loss?

Hair loss or thinning of the hair is documented as a less common or rare adverse reaction in official safety information.

Q: Can I take pain relievers like ibuprofen with Sulfazine?

Official regulatory documents indicate that combining Sulfazine with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may increase the risk of certain adverse effects. This includes a potential increased risk of harm to the kidneys.

Q: Does Sulfazine interact with birth control pills?

Yes, regulatory information documents that Sulfazine may reduce the effectiveness of some types of oral contraceptives (birth control pills). This is a documented possibility, and official information suggests discussing contraception options with a healthcare provider.

Q: Is Sulfazine known to cause weight gain or loss?

Decreased weight and loss of appetite are documented adverse reactions associated with this medication, according to official safety information.

Q: What is the 'black box warning' mentioned for Sulfazine?

Official warnings extensively document the most serious risks associated with this medication, which are often highlighted prominently in the prescribing information. These risks include potentially fatal blood disorders, liver and kidney damage, and severe skin reactions.

Q: Does Sulfazine have a generic version available?

Yes. A generic version of this medication has been approved by the FDA (Food and Drug Administration) for use in the United States.

Q: Is it necessary to avoid alcohol completely while on Sulfazine?

Official patient information notes that stomach problems may be more likely to occur if consuming alcoholic beverages while taking this medication. This precaution is noted in patient information.

Q: What happens if Sulfazine is exposed to sunlight?

Official patient safety information includes warnings about potential increased sensitivity to the sun (photosensitivity). Official information recommends the use of protective clothing and sunscreen while taking the medication to reduce the risk of reactions.

Q: How long does Sulfazine stay in your system after stopping?

Regulatory information indicates that one of the active components, Sulfapyridine, has been documented to remain detectable in the bloodstream for up to 3 days after the medication is stopped.

Q: Is Sulfazine only available by prescription?

Yes. This medication is classified by regulatory authorities as a prescription-only drug and is not available over the counter.

How should Sulfazine be stored and disposed of?

How to Store and Dispose of Sulfazine (Sulfasalazine)

Sulfasalazine must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at 25°C (77°F) (Controlled Room Temperature); excursions are permitted between 15°C and 30°C [NIH / DailyMed].
Protection Keep the container tightly closed and protect the medicine from excessive moisture and freezing [NIH / MedlinePlus].
Child Safety Store the tablets safely out of the sight and reach of children [NIH / MedlinePlus].

Disposal

Expired or unused tablets must be disposed of in accordance with local, regional, and national regulations [General Regulatory Mandate]. Medicines should not be poured down a sink or toilet, which prevents improper release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulfazine found in:

A-Z Index: